Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

12-Week, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Metformin DR in Subjects With Type 2 Diabetes Mellitus
12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Delayed-Release Metformin in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/22/2013
Clinical Research Facility
mi
from
Portland, OR
12-Week, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Metformin DR in Subjects With Type 2 Diabetes Mellitus
12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Delayed-Release Metformin in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/22/2013
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
12-Week, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Metformin DR in Subjects With Type 2 Diabetes Mellitus
12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Delayed-Release Metformin in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/22/2013
Clinical Research Facility
mi
from
Charleston, SC
12-Week, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Metformin DR in Subjects With Type 2 Diabetes Mellitus
12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Delayed-Release Metformin in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/22/2013
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
12-Week, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Metformin DR in Subjects With Type 2 Diabetes Mellitus
12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Delayed-Release Metformin in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/22/2013
Clinical Research Facility
mi
from
Dallas, TX
12-Week, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Metformin DR in Subjects With Type 2 Diabetes Mellitus
12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Delayed-Release Metformin in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/22/2013
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
12-Week, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Metformin DR in Subjects With Type 2 Diabetes Mellitus
12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Delayed-Release Metformin in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/22/2013
Clinical Research Facility
mi
from
Norfolk, VA
12-Week, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Metformin DR in Subjects With Type 2 Diabetes Mellitus
12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Delayed-Release Metformin in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/22/2013
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
12-Week, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Metformin DR in Subjects With Type 2 Diabetes Mellitus
12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Delayed-Release Metformin in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/22/2013
Clinical Research Facility
mi
from
Seattle, WA
12-Week, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Metformin DR in Subjects With Type 2 Diabetes Mellitus
12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Delayed-Release Metformin in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/22/2013
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Outpatient Automated Blood Glucose Control With a Bi-hormonal Bionic Endocrine Pancreas
The Beacon Hill Study: Feasibility of Outpatient Automated Blood Glucose Control With a Bi-hormonal Bionic Endocrine Pancreas
Status: Enrolling
Updated:  3/27/2013
Massachusetts General Hospital
mi
from
Boston, MA
Outpatient Automated Blood Glucose Control With a Bi-hormonal Bionic Endocrine Pancreas
The Beacon Hill Study: Feasibility of Outpatient Automated Blood Glucose Control With a Bi-hormonal Bionic Endocrine Pancreas
Status: Enrolling
Updated: 3/27/2013
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated:  3/28/2013
Cochise Clinical Research
mi
from
Sierra Vista, AZ
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated: 3/28/2013
Cochise Clinical Research
mi
from
Sierra Vista, AZ
Click here to add this to my saved trials
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated:  3/28/2013
University Clinical Investigators, Inc. dba Diabetes Research Center
mi
from
Tustin,, CA
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated: 3/28/2013
University Clinical Investigators, Inc. dba Diabetes Research Center
mi
from
Tustin,, CA
Click here to add this to my saved trials
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated:  3/28/2013
International Research Associates
mi
from
Miami, FL
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated: 3/28/2013
International Research Associates
mi
from
Miami, FL
Click here to add this to my saved trials
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated:  3/28/2013
The Center for Diabetes and Endocrine Care
mi
from
Hollywood, FL
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated: 3/28/2013
The Center for Diabetes and Endocrine Care
mi
from
Hollywood, FL
Click here to add this to my saved trials
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated:  3/28/2013
FPA Clinical Research
mi
from
Kissimmee,, FL
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated: 3/28/2013
FPA Clinical Research
mi
from
Kissimmee,, FL
Click here to add this to my saved trials
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated:  3/28/2013
Baptist Diabetes Associates, PA
mi
from
Miami, FL
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated: 3/28/2013
Baptist Diabetes Associates, PA
mi
from
Miami, FL
Click here to add this to my saved trials
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated:  3/28/2013
Suncoast Clinical Research
mi
from
Palm Harbor, FL
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated: 3/28/2013
Suncoast Clinical Research
mi
from
Palm Harbor, FL
Click here to add this to my saved trials
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated:  3/28/2013
Ormond Medical Arts Pharmaceutical Research Center
mi
from
Ormond Beach, FL
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated: 3/28/2013
Ormond Medical Arts Pharmaceutical Research Center
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated:  3/28/2013
International Clinical Research - US, LLC
mi
from
Sanford, FL
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated: 3/28/2013
International Clinical Research - US, LLC
mi
from
Sanford, FL
Click here to add this to my saved trials
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated:  3/28/2013
Cotton-O'Neil Clinical Research Center, Diabetes & Endocrinology
mi
from
Topeka, KA
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated: 3/28/2013
Cotton-O'Neil Clinical Research Center, Diabetes & Endocrinology
mi
from
Topeka, KA
Click here to add this to my saved trials
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated:  3/28/2013
Kentucky Diabetes Endocrinology Center
mi
from
Lexington, KY
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated: 3/28/2013
Kentucky Diabetes Endocrinology Center
mi
from
Lexington, KY
Click here to add this to my saved trials
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated:  3/28/2013
Endocrine & Metabolic Consultants
mi
from
Rockville,, MD
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated: 3/28/2013
Endocrine & Metabolic Consultants
mi
from
Rockville,, MD
Click here to add this to my saved trials
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated:  3/28/2013
ActivMed Practices and Research
mi
from
Haverhill, MA
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated: 3/28/2013
ActivMed Practices and Research
mi
from
Haverhill, MA
Click here to add this to my saved trials
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated:  3/28/2013
Alzohaili Medical Consultants
mi
from
Dearborn, MI
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated: 3/28/2013
Alzohaili Medical Consultants
mi
from
Dearborn, MI
Click here to add this to my saved trials
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated:  3/28/2013
Apex Medical Research
mi
from
Flint, MI
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated: 3/28/2013
Apex Medical Research
mi
from
Flint, MI
Click here to add this to my saved trials
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated:  3/28/2013
ActivMed Practices and Research
mi
from
Rochester, NH
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated: 3/28/2013
ActivMed Practices and Research
mi
from
Rochester, NH
Click here to add this to my saved trials
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated:  3/28/2013
Premier Research
mi
from
Trenton, NJ
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated: 3/28/2013
Premier Research
mi
from
Trenton, NJ
Click here to add this to my saved trials
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated:  3/28/2013
Ellipsis Research Group, LLC
mi
from
Columbia, SC
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated: 3/28/2013
Ellipsis Research Group, LLC
mi
from
Columbia, SC
Click here to add this to my saved trials
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated:  3/28/2013
University Diabetes & Endocrine Association
mi
from
Chattanooga, TN
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated: 3/28/2013
University Diabetes & Endocrine Association
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated:  3/28/2013
Sergio Rovner, MD
mi
from
El Paso, TX
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated: 3/28/2013
Sergio Rovner, MD
mi
from
El Paso, TX
Click here to add this to my saved trials
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated:  3/28/2013
Optimum Clinical Research
mi
from
Salt Lake City, UT
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated: 3/28/2013
Optimum Clinical Research
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated:  3/28/2013
Dominion Medical Associates
mi
from
Richmond, VA
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Status: Enrolling
Updated: 3/28/2013
Dominion Medical Associates
mi
from
Richmond, VA
Click here to add this to my saved trials
Squalamine for the Treatment in Proliferative Diabetic Retinopathy
Topical Squalamine in the Treatment of Retinal Neovascularization From Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  4/10/2013
Elman Retina Group, PA
mi
from
Baltimore, MD
Squalamine for the Treatment in Proliferative Diabetic Retinopathy
Topical Squalamine in the Treatment of Retinal Neovascularization From Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 4/10/2013
Elman Retina Group, PA
mi
from
Baltimore, MD
Click here to add this to my saved trials
The Summer Camp Study: Blood Glucose Control With a Bi-Hormonal Bionic Endocrine Pancreas
The Summer Camp Study: Feasibility of Outpatient Automated Blood Glucose Control With a Bi-Hormonal Bionic Endocrine Pancreas in a Pediatric Population at the Clara Barton Diabetes Camps
Status: Enrolling
Updated:  4/13/2013
Massachusetts General Hospital
mi
from
Boston, MA
The Summer Camp Study: Blood Glucose Control With a Bi-Hormonal Bionic Endocrine Pancreas
The Summer Camp Study: Feasibility of Outpatient Automated Blood Glucose Control With a Bi-Hormonal Bionic Endocrine Pancreas in a Pediatric Population at the Clara Barton Diabetes Camps
Status: Enrolling
Updated: 4/13/2013
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Metabolomic Analysis of Hepatic Insulin Resistance
Metabolomic Analysis of Hepatic Insulin Resistance
Status: Enrolling
Updated:  4/15/2013
Univ of Minnesota
mi
from
Minneapolis, MN
Metabolomic Analysis of Hepatic Insulin Resistance
Metabolomic Analysis of Hepatic Insulin Resistance
Status: Enrolling
Updated: 4/15/2013
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics
Wound EMR to Decrease Limb Amputations in Persons With Diabetes
Status: Enrolling
Updated:  4/16/2013
Aiyan Diabetes Center
mi
from
Evans, GA
Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics
Wound EMR to Decrease Limb Amputations in Persons With Diabetes
Status: Enrolling
Updated: 4/16/2013
Aiyan Diabetes Center
mi
from
Evans, GA
Click here to add this to my saved trials
Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics
Wound EMR to Decrease Limb Amputations in Persons With Diabetes
Status: Enrolling
Updated:  4/16/2013
Bellevue Hospital
mi
from
New York, NY
Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics
Wound EMR to Decrease Limb Amputations in Persons With Diabetes
Status: Enrolling
Updated: 4/16/2013
Bellevue Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics
Wound EMR to Decrease Limb Amputations in Persons With Diabetes
Status: Enrolling
Updated:  4/16/2013
Elks Wound Center
mi
from
Meridian, ID
Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics
Wound EMR to Decrease Limb Amputations in Persons With Diabetes
Status: Enrolling
Updated: 4/16/2013
Elks Wound Center
mi
from
Meridian, ID
Click here to add this to my saved trials
Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics
Wound EMR to Decrease Limb Amputations in Persons With Diabetes
Status: Enrolling
Updated:  4/16/2013
Georgetown University Medical Center
mi
from
Washington,
Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics
Wound EMR to Decrease Limb Amputations in Persons With Diabetes
Status: Enrolling
Updated: 4/16/2013
Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics
Wound EMR to Decrease Limb Amputations in Persons With Diabetes
Status: Enrolling
Updated:  4/16/2013
Lincoln Hospital
mi
from
New York, NY
Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics
Wound EMR to Decrease Limb Amputations in Persons With Diabetes
Status: Enrolling
Updated: 4/16/2013
Lincoln Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics
Wound EMR to Decrease Limb Amputations in Persons With Diabetes
Status: Enrolling
Updated:  4/16/2013
Mayo Clinic Rochester
mi
from
Rochester, MN
Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics
Wound EMR to Decrease Limb Amputations in Persons With Diabetes
Status: Enrolling
Updated: 4/16/2013
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics
Wound EMR to Decrease Limb Amputations in Persons With Diabetes
Status: Enrolling
Updated:  4/16/2013
Memorial Healthcare System
mi
from
Hollywood, FL
Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics
Wound EMR to Decrease Limb Amputations in Persons With Diabetes
Status: Enrolling
Updated: 4/16/2013
Memorial Healthcare System
mi
from
Hollywood, FL
Click here to add this to my saved trials
Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics
Wound EMR to Decrease Limb Amputations in Persons With Diabetes
Status: Enrolling
Updated:  4/16/2013
Metropolitan Hospital
mi
from
New York, NY
Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics
Wound EMR to Decrease Limb Amputations in Persons With Diabetes
Status: Enrolling
Updated: 4/16/2013
Metropolitan Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics
Wound EMR to Decrease Limb Amputations in Persons With Diabetes
Status: Enrolling
Updated:  4/16/2013
North Shore - Long Island Jewish Health System
mi
from
Lake Success, NY
Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics
Wound EMR to Decrease Limb Amputations in Persons With Diabetes
Status: Enrolling
Updated: 4/16/2013
North Shore - Long Island Jewish Health System
mi
from
Lake Success, NY
Click here to add this to my saved trials
Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics
Wound EMR to Decrease Limb Amputations in Persons With Diabetes
Status: Enrolling
Updated:  4/16/2013
Phoenix VA Hospital
mi
from
Phoenix, AZ
Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics
Wound EMR to Decrease Limb Amputations in Persons With Diabetes
Status: Enrolling
Updated: 4/16/2013
Phoenix VA Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics
Wound EMR to Decrease Limb Amputations in Persons With Diabetes
Status: Enrolling
Updated:  4/16/2013
University of Arizona
mi
from
Tuscon, AZ
Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics
Wound EMR to Decrease Limb Amputations in Persons With Diabetes
Status: Enrolling
Updated: 4/16/2013
University of Arizona
mi
from
Tuscon, AZ
Click here to add this to my saved trials
Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics
Wound EMR to Decrease Limb Amputations in Persons With Diabetes
Status: Enrolling
Updated:  4/16/2013
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics
Wound EMR to Decrease Limb Amputations in Persons With Diabetes
Status: Enrolling
Updated: 4/16/2013
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics
Wound EMR to Decrease Limb Amputations in Persons With Diabetes
Status: Enrolling
Updated:  4/16/2013
Western University of Health Sciences
mi
from
Pomona, CA
Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics
Wound EMR to Decrease Limb Amputations in Persons With Diabetes
Status: Enrolling
Updated: 4/16/2013
Western University of Health Sciences
mi
from
Pomona, CA
Click here to add this to my saved trials
Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus
Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  4/19/2013
University of Virginia
mi
from
Charlottesville, VA
Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus
Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 4/19/2013
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Clinical Evaluation of the Combined Use of Apligraf® and the SNaP® Pressure Wound Therapy System
Clinical Evaluation of the Combined Use of Apligraf® and the SNaP® Negative Pressure Wound Therapy System for Treatment of Non-responding Venous Stasis and Diabetic Lower Extremity Ulcers
Status: Enrolling
Updated:  4/23/2013
O'Connor Hospital - Wound Care Center
mi
from
San Jose, CA
Clinical Evaluation of the Combined Use of Apligraf® and the SNaP® Pressure Wound Therapy System
Clinical Evaluation of the Combined Use of Apligraf® and the SNaP® Negative Pressure Wound Therapy System for Treatment of Non-responding Venous Stasis and Diabetic Lower Extremity Ulcers
Status: Enrolling
Updated: 4/23/2013
O'Connor Hospital - Wound Care Center
mi
from
San Jose, CA
Click here to add this to my saved trials
NEAT! Technology to Increase Breaks in Sedentary Behavior in Adults With Diabetes
NEAT! Technology to Increase Breaks in Sedentary Behavior in Adults With Diabetes
Status: Enrolling
Updated:  4/24/2013
Northwestern University
mi
from
Chicago, IL
NEAT! Technology to Increase Breaks in Sedentary Behavior in Adults With Diabetes
NEAT! Technology to Increase Breaks in Sedentary Behavior in Adults With Diabetes
Status: Enrolling
Updated: 4/24/2013
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass
The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass
Status: Enrolling
Updated:  4/26/2013
Mayo Clinic Rochester
mi
from
Rochester, MN
The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass
The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass
Status: Enrolling
Updated: 4/26/2013
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass
The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass
Status: Enrolling
Updated:  4/26/2013
Mayo Clinic Rochester
mi
from
Rochester, MN
The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass
The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass
Status: Enrolling
Updated: 4/26/2013
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
A Pilot Intervention Study of Health Coaching to Promote Diabetes Self-Care in the Community
Coaching for Control: A Pilot Intervention Study of Health Coaching to Promote Diabetes Self-Care in the Community
Status: Enrolling
Updated:  5/3/2013
Northwestern University
mi
from
Chicago, IL
A Pilot Intervention Study of Health Coaching to Promote Diabetes Self-Care in the Community
Coaching for Control: A Pilot Intervention Study of Health Coaching to Promote Diabetes Self-Care in the Community
Status: Enrolling
Updated: 5/3/2013
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials